PortalPublikationenOptimising clinical trials in acute myocardial infarction co...

Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop

Standard

Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop. / Arrigo, Mattia; Price, Susanna; Baran, David A; Pöss, Janine; Aissaoui, Nadia; Bayes-Genis, Antoni; Bonello, Laurent; François, Bruno; Gayat, Etienne; Gilard, Martine; Kapur, Navin K; Karakas, Mahir; Kostrubiec, Maciej; Leprince, Pascal; Levy, Bruno; Rosenberg, Yves; Thiele, Holger; Zeymer, Uwe; Harhay, Michael O; Mebazaa, Alexandre.

in: LANCET RESP MED, Jahrgang 9, Nr. 10, 10.2021, S. 1192-1202.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Arrigo, M, Price, S, Baran, DA, Pöss, J, Aissaoui, N, Bayes-Genis, A, Bonello, L, François, B, Gayat, E, Gilard, M, Kapur, NK, Karakas, M, Kostrubiec, M, Leprince, P, Levy, B, Rosenberg, Y, Thiele, H, Zeymer, U, Harhay, MO & Mebazaa, A 2021, 'Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop', LANCET RESP MED, Jg. 9, Nr. 10, S. 1192-1202. https://doi.org/10.1016/S2213-2600(21)00172-7

APA

Arrigo, M., Price, S., Baran, D. A., Pöss, J., Aissaoui, N., Bayes-Genis, A., Bonello, L., François, B., Gayat, E., Gilard, M., Kapur, N. K., Karakas, M., Kostrubiec, M., Leprince, P., Levy, B., Rosenberg, Y., Thiele, H., Zeymer, U., Harhay, M. O., & Mebazaa, A. (2021). Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop. LANCET RESP MED, 9(10), 1192-1202. https://doi.org/10.1016/S2213-2600(21)00172-7

Vancouver

Arrigo M, Price S, Baran DA, Pöss J, Aissaoui N, Bayes-Genis A et al. Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop. LANCET RESP MED. 2021 Okt;9(10):1192-1202. https://doi.org/10.1016/S2213-2600(21)00172-7

Bibtex

@article{a962ae1e3b8d42d499be180361edae55,
title = "Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop",
abstract = "Acute myocardial infarction complicated by cardiogenic shock (AMICS) is a critical syndrome with a high risk of morbidity and mortality. Current management consists of coronary revascularisation, vasoactive drugs, and circulatory and ventilatory support, which are tailored to patients mainly on the basis of clinicians' experience rather than evidence-based recommendations. For many therapeutic interventions in AMICS, randomised clinical trials have not shown a meaningful survival benefit, and a disproportionately high rate of neutral and negative results has been reported. In this context, an accurate definition of the AMICS syndrome for appropriate patient selection and optimisation of study design are warranted to achieve meaningful results and pave the way for new, evidence-based therapeutic options. In this Position Paper, we provide a statement of priorities and recommendations agreed by a multidisciplinary group of experts at the Critical Care Clinical Trialists Workshop in February, 2020, for the optimisation and harmonisation of clinical trials in AMICS. Implementation of proposed criteria to define the AMICS population-moving beyond a cardio-centric definition to that of a systemic disease-and steps to improve the design of clinical trials could lead to improved outcomes for patients with this life-threatening syndrome.",
author = "Mattia Arrigo and Susanna Price and Baran, {David A} and Janine P{\"o}ss and Nadia Aissaoui and Antoni Bayes-Genis and Laurent Bonello and Bruno Fran{\c c}ois and Etienne Gayat and Martine Gilard and Kapur, {Navin K} and Mahir Karakas and Maciej Kostrubiec and Pascal Leprince and Bruno Levy and Yves Rosenberg and Holger Thiele and Uwe Zeymer and Harhay, {Michael O} and Alexandre Mebazaa",
year = "2021",
month = oct,
doi = "10.1016/S2213-2600(21)00172-7",
language = "English",
volume = "9",
pages = "1192--1202",
journal = "LANCET RESP MED",
issn = "2213-2600",
publisher = "Elsevier Limited",
number = "10",

}

RIS

TY - JOUR

T1 - Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop

AU - Arrigo, Mattia

AU - Price, Susanna

AU - Baran, David A

AU - Pöss, Janine

AU - Aissaoui, Nadia

AU - Bayes-Genis, Antoni

AU - Bonello, Laurent

AU - François, Bruno

AU - Gayat, Etienne

AU - Gilard, Martine

AU - Kapur, Navin K

AU - Karakas, Mahir

AU - Kostrubiec, Maciej

AU - Leprince, Pascal

AU - Levy, Bruno

AU - Rosenberg, Yves

AU - Thiele, Holger

AU - Zeymer, Uwe

AU - Harhay, Michael O

AU - Mebazaa, Alexandre

PY - 2021/10

Y1 - 2021/10

N2 - Acute myocardial infarction complicated by cardiogenic shock (AMICS) is a critical syndrome with a high risk of morbidity and mortality. Current management consists of coronary revascularisation, vasoactive drugs, and circulatory and ventilatory support, which are tailored to patients mainly on the basis of clinicians' experience rather than evidence-based recommendations. For many therapeutic interventions in AMICS, randomised clinical trials have not shown a meaningful survival benefit, and a disproportionately high rate of neutral and negative results has been reported. In this context, an accurate definition of the AMICS syndrome for appropriate patient selection and optimisation of study design are warranted to achieve meaningful results and pave the way for new, evidence-based therapeutic options. In this Position Paper, we provide a statement of priorities and recommendations agreed by a multidisciplinary group of experts at the Critical Care Clinical Trialists Workshop in February, 2020, for the optimisation and harmonisation of clinical trials in AMICS. Implementation of proposed criteria to define the AMICS population-moving beyond a cardio-centric definition to that of a systemic disease-and steps to improve the design of clinical trials could lead to improved outcomes for patients with this life-threatening syndrome.

AB - Acute myocardial infarction complicated by cardiogenic shock (AMICS) is a critical syndrome with a high risk of morbidity and mortality. Current management consists of coronary revascularisation, vasoactive drugs, and circulatory and ventilatory support, which are tailored to patients mainly on the basis of clinicians' experience rather than evidence-based recommendations. For many therapeutic interventions in AMICS, randomised clinical trials have not shown a meaningful survival benefit, and a disproportionately high rate of neutral and negative results has been reported. In this context, an accurate definition of the AMICS syndrome for appropriate patient selection and optimisation of study design are warranted to achieve meaningful results and pave the way for new, evidence-based therapeutic options. In this Position Paper, we provide a statement of priorities and recommendations agreed by a multidisciplinary group of experts at the Critical Care Clinical Trialists Workshop in February, 2020, for the optimisation and harmonisation of clinical trials in AMICS. Implementation of proposed criteria to define the AMICS population-moving beyond a cardio-centric definition to that of a systemic disease-and steps to improve the design of clinical trials could lead to improved outcomes for patients with this life-threatening syndrome.

U2 - 10.1016/S2213-2600(21)00172-7

DO - 10.1016/S2213-2600(21)00172-7

M3 - SCORING: Review article

C2 - 34245691

VL - 9

SP - 1192

EP - 1202

JO - LANCET RESP MED

JF - LANCET RESP MED

SN - 2213-2600

IS - 10

ER -